320 related articles for article (PubMed ID: 26951234)
1. Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies.
Mikačić I; Bosnar D
Drug Saf; 2016 Jun; 39(6):517-41. PubMed ID: 26951234
[TBL] [Abstract][Full Text] [Related]
2. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.
Moja L; Lucenteforte E; Kwag KH; Bertele V; Campomori A; Chakravarthy U; D'Amico R; Dickersin K; Kodjikian L; Lindsley K; Loke Y; Maguire M; Martin DF; Mugelli A; Mühlbauer B; Püntmann I; Reeves B; Rogers C; Schmucker C; Subramanian ML; Virgili G
Cochrane Database Syst Rev; 2014 Sep; 9(9):CD011230. PubMed ID: 25220133
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.
Thulliez M; Angoulvant D; Le Lez ML; Jonville-Bera AP; Pisella PJ; Gueyffier F; Bejan-Angoulvant T
JAMA Ophthalmol; 2014 Nov; 132(11):1317-26. PubMed ID: 25058694
[TBL] [Abstract][Full Text] [Related]
4. Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials.
Ueta T; Noda Y; Toyama T; Yamaguchi T; Amano S
Ophthalmology; 2014 Nov; 121(11):2193-203.e1-7. PubMed ID: 25023760
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review.
Schmucker C; Loke YK; Ehlken C; Agostini HT; Hansen LL; Antes G; Lelgemann M
Br J Ophthalmol; 2011 Mar; 95(3):308-17. PubMed ID: 20971791
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal Bevacizumab Versus Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration: Findings from a Cochrane Systematic Review.
Solomon SD; Lindsley KB; Krzystolik MG; Vedula SS; Hawkins BS
Ophthalmology; 2016 Jan; 123(1):70-77.e1. PubMed ID: 26477843
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab.
Mitchell P
Curr Med Res Opin; 2011 Jul; 27(7):1465-75. PubMed ID: 21623685
[TBL] [Abstract][Full Text] [Related]
8. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.
Campbell RJ; Bell CM; Paterson JM; Bronskill SE; Moineddin R; Whitehead M; Gill SS
Ophthalmology; 2012 Aug; 119(8):1604-8. PubMed ID: 22717458
[TBL] [Abstract][Full Text] [Related]
9. Macular grid laser photocoagulation for branch retinal vein occlusion.
Lam FC; Chia SN; Lee RM
Cochrane Database Syst Rev; 2015 May; 2015(5):CD008732. PubMed ID: 25961835
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials.
Chen G; Li W; Tzekov R; Jiang F; Mao S; Tong Y
Retina; 2015 Feb; 35(2):187-93. PubMed ID: 25105318
[TBL] [Abstract][Full Text] [Related]
12. Safety Assessment and Power Analyses in Published Anti-Vascular Endothelial Growth Factor Randomized Controlled Trials.
Esen F; Alhan O; Kuru P; Sahin O
Am J Ophthalmol; 2016 Sep; 169():68-72. PubMed ID: 27320058
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review.
Schmucker C; Ehlken C; Hansen LL; Antes G; Agostini HT; Lelgemann M
Curr Opin Ophthalmol; 2010 May; 21(3):218-26. PubMed ID: 20393293
[TBL] [Abstract][Full Text] [Related]
14. Photodynamic therapy in combination with ranibizumab versus ranibizumab monotherapy for wet age-related macular degeneration: A systematic review and meta-analysis.
Su Y; Wu J; Gu Y
Photodiagnosis Photodyn Ther; 2018 Jun; 22():263-273. PubMed ID: 29753123
[TBL] [Abstract][Full Text] [Related]
15. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.
Takeda AL; Colquitt J; Clegg AJ; Jones J
Br J Ophthalmol; 2007 Sep; 91(9):1177-82. PubMed ID: 17475698
[TBL] [Abstract][Full Text] [Related]
16. The safety of bevacizumab and ranibizumab in clinical studies.
De Rosa M; Messori A
Int Ophthalmol; 2015 Apr; 35(2):157-8. PubMed ID: 25646753
[TBL] [Abstract][Full Text] [Related]
17. Vascular Safety of Ranibizumab in Patients With Diabetic Macular Edema: A Pooled Analysis of Patient-Level Data From Randomized Clinical Trials.
Zarbin MA; Dunger-Baldauf C; Haskova Z; Koovejee P; Mousseau MC; Margaron P; Snow H; Beaumont PE; Staurenghi G; Francom S
JAMA Ophthalmol; 2017 May; 135(5):424-431. PubMed ID: 28384675
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab (AVASTIN) and age-related macular degeneration. Lower cost does not justify taking risks.
Prescrire Int; 2015 Sep; 24(163):201-4. PubMed ID: 26417625
[TBL] [Abstract][Full Text] [Related]
19. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
Kourlas H; Abrams P
Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of cardiovascular diseases after the upload phase with intravitreal ranibizumab and bevacizumab in patients with exudative age-related macular degeneration].
Fischer C; Schäfer K; Dschietzig T; Hoerauf H
Ophthalmologe; 2016 Jul; 113(7):589-95. PubMed ID: 26801323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
